These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 14120951)

  • 1. ADMINISTRATION OF DIHYDROXYPHENYLALANINE TO PARKINSONIAN PATIENTS.
    MCGEER PL; ZELDOWICZ LR
    Can Med Assoc J; 1964 Feb; 90(7):463-6. PubMed ID: 14120951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
    TRAVENED I
    Cas Lek Cesk; 1964 Jun; 103():748-52. PubMed ID: 14178689
    [No Abstract]   [Full Text] [Related]  

  • 3. [PATHOGENESIS OF THE BASIC SYMPTOMS OF PARKINSONISM DUE TO BIOCHEMICAL CHANGES IN THE SUBCORTICAL AND STEM STRUCTURES OF THE EXTRAPYRAMIDAL SYSTEM].
    TRAVENEC I
    Cas Lek Cesk; 1964 Jun; 103():748-52. PubMed ID: 14180121
    [No Abstract]   [Full Text] [Related]  

  • 4. [ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
    HIRSCHMANN J; MAYER K
    Dtsch Med Wochenschr; 1964 Oct; 89():1877-80. PubMed ID: 14211843
    [No Abstract]   [Full Text] [Related]  

  • 5. A CLINICAL AND METABOLIC STUDY OF DOPA (3, 4-DIHYDROXYPHENYLALANINE) AND METHYLDOPA IN HUNTINGTON'S CHOREA.
    SOURKES TL; PIVNICKI D; BROWN WT; WISEMAN-DISTLER H; MURPHY GF; SANKOFF I; SAINTCYR S
    Psychiatr Neurol (Basel); 1965; 149():7-27. PubMed ID: 14291283
    [No Abstract]   [Full Text] [Related]  

  • 6. [NEW MEANS OF CONTROLLING EXTRAPYRAMIDAL MOTOR DISORDERS].
    HIRSCHMANN J; MAYER K
    Arzneimittelforschung; 1964 Jun; 14():SUPPL:599-601. PubMed ID: 14253979
    [No Abstract]   [Full Text] [Related]  

  • 7. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R
    Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
    [No Abstract]   [Full Text] [Related]  

  • 8. CAMPOTOMY IN VARIOUS EXTRAPYRAMIDAL DISORDERS.
    SPIEGEL EA; WYCIS HT; SZEKELY EG; ADAMS DJ; FLANAGAN M; BAIRD HW
    J Neurosurg; 1963 Oct; 20():871-84. PubMed ID: 14186082
    [No Abstract]   [Full Text] [Related]  

  • 9. [ANATOMICAL FINDINGS IN SUBJECTS UNDERGOING STEREOTAXIC THALAMOTOMY].
    MACCHI G; DALLEORE G; DAPIAN R
    Sist Nerv; 1964; 16():193-223. PubMed ID: 14211192
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys.
    Hsu A; Togasaki DM; Bezard E; Sokoloff P; Langston JW; Di Monte DA; Quik M
    J Pharmacol Exp Ther; 2004 Nov; 311(2):770-7. PubMed ID: 15226382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INTERCHANGEABLITY OF ANTIPARKINSONIAN MEDICATION.
    STJEAN A; DONALD M; BAN TA
    Am J Psychiatry; 1964 Jun; 120():1189-90. PubMed ID: 14154754
    [No Abstract]   [Full Text] [Related]  

  • 12. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies on the metabolism of D- and L-isomers of 3,4-dihydroxyphenylalanine (DOPA). 3. Absorption, distribution and excretion of D- and L-DOPA-14C in rats following intravenous and oral administration.
    Shindo H; Nakajima E; Kawai K; Miyakoshi N; Tanaka K
    Chem Pharm Bull (Tokyo); 1973 Apr; 21(4):817-25. PubMed ID: 4727354
    [No Abstract]   [Full Text] [Related]  

  • 14. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism.
    Naskar A; Manivasagam T; Chakraborty J; Singh R; Thomas B; Dhanasekaran M; Mohanakumar KP
    J Pineal Res; 2013 Oct; 55(3):304-12. PubMed ID: 23952687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral and intravenous administrations of dopamine and L-dopa on plasma levels of two isomers of dopamine sulfate in man.
    Hashizume K; Yamatodani A; Yamamoto T; Ogihara T; Kumahara Y; Wada H
    Life Sci; 1987 Dec; 41(25):2697-704. PubMed ID: 3695802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dopaminergic conception of Parkinsonism and its treatment with L-DOPA].
    Levin SL
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(9):1418-26. PubMed ID: 4349303
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
    Abdin AA; Hamouda HE
    Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion and metabolism of dopa and dopamine by isolated perfused rat kidney.
    Suzuki H; Nakane H; Kawamura M; Yoshizawa M; Takeshita E; Saruta T
    Am J Physiol; 1984 Sep; 247(3 Pt 1):E285-90. PubMed ID: 6433718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.